Jisoo Kmd Baek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jisoo Kmd Baek has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Chungsik Kmd Cho
Department of Internal Korean Medicine, College of Korean Medicine, Dae-Jeon University, Daejeon, Republic of Korea
1 shared publicationJinmi Kmd Kim
Department of Internal Korean Medicine, College of Korean Medicine, Dae-Jeon University, Daejeon, Republic of Korea
1 shared publicationSeonmi Kmd Shin
Department. of Internal Korean Medicine, College of Korean Medicine, Se-Myung University, Chungcheongbukdo, South Korea
1 shared publication
Latest Publications
- Open Access
- 18 March 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (11)
The efficacy and safety of yukmijihwang-hwan (Liuweidihuang-wan) for type 2 diabetes mellitus without complications
Background: This systematic review and meta-analysis of randomized controlled trials (RCTs) will aim to assess the efficacy and safety of Yukmijihwang-hwan for type 2 diabetes without complications. Methods: To identify eligible studies, we will perform a systematic search of the following electronic databases: MEDLINE (PubMed), EMBASE, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Citation Information by NII, Korean Information Service System, Korean Medical Database, Oriental Medicine Advanced Searching Integrated System, and ScienceON. Search terms will include “Type 2 Diabetes” for participants as well as “Yukmijihwang-tang” or “Liuwei dihuang tang” for interventions. Two independent researchers will perform data extraction and assessment using Cochrane’s risk of bias tool, with disagreements being resolved through discussions with a third researcher. Results: This study will evaluate the antidiabetic effects of Yukmijihwang-hwan from 3 perspectives (blood glucose level, insulin resistance, and β-cell function) as well as its safety by reviewing the reported adverse effects. Conclusion: This systematic review will provide evidence regarding the antidiabetic efficacy and safety of Yukmijihwang-tang in type 2 diabetes mellitus.
- 18 March 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (11)
Open AccessThe efficacy and safety of yukmijihwang-hwan (Liuweidihuang-wan) for type 2 diabetes mellitus without complications
Background: This systematic review and meta-analysis of randomized controlled trials (RCTs) will aim to assess the efficacy and safety of Yukmijihwang-hwan for type 2 diabetes without complications. Methods: To identify eligible studies, we will perform a systematic search of the following electronic databases: MEDLINE (PubMed), EMBASE, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Citation Information by NII, Korean Information Service System, Korean Medical Database, Oriental Medicine Advanced Searching Integrated System, and ScienceON. Search terms will include “Type 2 Diabetes” for participants as well as “Yukmijihwang-tang” or “Liuwei dihuang tang” for interventions. Two independent researchers will perform data extraction and assessment using Cochrane’s risk of bias tool, with disagreements being resolved through discussions with a third researcher. Results: This study will evaluate the antidiabetic effects of Yukmijihwang-hwan from 3 perspectives (blood glucose level, insulin resistance, and β-cell function) as well as its safety by reviewing the reported adverse effects. Conclusion: This systematic review will provide evidence regarding the antidiabetic efficacy and safety of Yukmijihwang-tang in type 2 diabetes mellitus.